---
title: "NXGL: Q2 revenue reached $3.69M with a $2.87M net loss; integration and expansion efforts continue"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296106108.md"
description: "Q2 2026 revenue was $3.69M with a net loss of $2.87M, impacted by non-recurring items and a strategic recall. Integration of acquisitions and expansion into hospital and regenerative medicine markets are underway, with supply chain and shareholder approval challenges persisting.Original document: NexGel, Inc [NXGL] SEC 8-K Current Report — Aug. 25 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-17T12:25:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296106108.md)
  - [en](https://longbridge.com/en/news/296106108.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296106108.md)
generator: "portal-rs"
---

# NXGL: Q2 revenue reached $3.69M with a $2.87M net loss; integration and expansion efforts continue

Q2 2026 revenue was $3.69M with a net loss of $2.87M, impacted by non-recurring items and a strategic recall. Integration of acquisitions and expansion into hospital and regenerative medicine markets are underway, with supply chain and shareholder approval challenges persisting.

Original document: NexGel, Inc \[NXGL\] SEC 8-K Current Report — Aug. 25 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [NXGL.US](https://longbridge.com/en/quote/NXGL.US.md)
- [NXGLW.US](https://longbridge.com/en/quote/NXGLW.US.md)

## Related News & Research

- [Nexgel’s Celularity Deal: Execution, Integration, and Profitability Risks from $13.3 Million Biomaterials Acquisition](https://longbridge.com/en/news/296183101.md)
- [THCH: Revenue and same-store sales fell sharply in Q2 2026 amid competition and strategic store closures](https://longbridge.com/en/news/296238737.md)
- [Regenerative Medical Technology Group announces investor call to address shareholder questions](https://longbridge.com/en/news/296410031.md)
- [WHF: Consistent dividends, strong returns, and strategic growth themes drive investor confidence](https://longbridge.com/en/news/296427169.md)
- [AIIR: H1'26 saw resilient revenue and stable Adjusted EBITDA amid disruption, with growth set to accelerate](https://longbridge.com/en/news/296476265.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**